The promise of hematopoietic stem cell transplantation for autoimmune diseases

R. K. Burt*, A. E. Traynor, R. Craig, A. M. Marmont

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations

Abstract

Hematopoietic stem cell transplantation (HSCT) is being increasingly utilized for the treatment of a whole spectrum of severe autoimmune diseases refractory to conventional therapy. Although allogeneic HSCT has been followed by durable complete remission in a restricted number of patients with coincidental disease, the autologous procedure is generally preferred because of its lesser toxicity. Most autoimmune diseases are the consequence of a multistep process, mainly originating from the interplay of genetic, environmental, and hormonal factors. It has been postulated that if immunosuppressive regimens can eliminate or effectively reduce the level of autoreactive T and B cells, then regeneration of de novo immunity even in the autologous setting may bypass the initial breakdown of self-tolerance and ensure prolonged disease remission. As mentioned in a recent review of this field, protocol design including conditioning regimen, patient selection, stem cell source and final outcome are likely to be disease-specific. The following is a summary of the 2002 International Bone Marrow Transplantation Registry/American Society of Blood and Bone Marrow Transplantation (IBMTR/ASBMT) satellite symposium in Orlando, Florida on 24 February 2002 on Expanding the Promise of Hematopoietic Stem Cell Transplantation in Autoimmune Diseases.

Original languageEnglish (US)
Pages (from-to)521-524
Number of pages4
JournalBone Marrow Transplantation
Volume31
Issue number7
DOIs
StatePublished - Apr 1 2003

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'The promise of hematopoietic stem cell transplantation for autoimmune diseases'. Together they form a unique fingerprint.

Cite this